Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-2
2022-001500-18Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigimadlin in biliary adenocarcinoma, pancreatic adenocarcinoma (PDAC) and Nonhematologic neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: objective response. Started Aug 2022; status: active.
02
Drugs
brigimadlin
03
Conditions
biliary adenocarcinomapancreatic adenocarcinoma (PDAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-001500-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001500-18.